Publications by authors named "C Dubrou"

We describe pulmonary cryptococcosis in a 28-year-old previously healthy man. Exhaustive immunological investigations revealed a primary NK cell deficiency associated with a secondary impaired anti-Cryptococcus CD8 lymphocyte response and the expansion of a CD8Vβ14 + T cell clone. This case illustrates the potential role of NK cells in immunity against Cryptococcus.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the role of anti-RNP autoantibodies in diagnosing mixed connective tissue disease (MCTD) and distinguishing it from systemic lupus erythematosus (SLE).
  • Researchers analyzed samples from 74 patients with anti-RNP autoantibodies, identifying that the ratio of autoantibodies targeting the U1-snRNP complex was significantly higher in MCTD patients compared to those with SLE.
  • Findings suggest that assessing the overall RNP index is a more reliable diagnostic tool than evaluating individual autoantibodies, with potential implications for predicting disease progression.
View Article and Find Full Text PDF

Background And Objectives: Patients with multiple sclerosis (PwMS) receiving extended dosing of rituximab (RTX) have exhibited no return of disease activity, which suggests that maintenance of deep depletion of circulating B cells is not necessary to maintain the efficacy of RTX in MS.

Methods: This was a prospective monocentric observational study including all consecutive PwMS who started or continued RTX after 2019, when the medical staff decided to extend the dosing interval up to 24 months for all patients. Circulating B-cell subsets were monitored regularly and systematically in case of relapse.

View Article and Find Full Text PDF

Context: Parkinson disease is a neurodegenerative disorder characterized by motor and non-motor symptoms. Symptomatic treatment is based on dopaminergic medications. In case of self-medication practices, there may be drug-drug interactions between over-the-counter medication and dopaminergic medications.

View Article and Find Full Text PDF

Levodopa (L-dopa) remains the basis of pharmacological treatment of Parkinson's disease (PD). However, L-dopa therapy is associated with the development of complications and presents major challenges in the long-term treatment. Thus, other medications may be suggested to delay and/or reduce the doses of L-dopa in order to prevent complications.

View Article and Find Full Text PDF